Polaris Market Research values the cannabis pharmaceuticals market at USD 5.30 billion in 2024, with growth from USD 8.07 billion in 2025 to USD 357.96 billion by 2034 at a CAGR of 52.4%. The report segments the market by brand type, distribution channel, and region. The leading brand-type share belongs to a CBD-based epilepsy medication approved by the US FDA. Sativex, a THC and CBD combination product, also maintains a significant presence, particularly for treating multiple sclerosis-related spasticity. Its growth has been relatively stable compared with the leading brand, as it faces competition from newer CBD-based treatments and shifting regulatory frameworks.

Other Brands Show the Highest Growth

The other brands segment is witnessing the highest growth, driven by the increasing number of cannabis-based pharmaceuticals entering the market. It benefits from rising investment in research and development as companies explore a wider range of cannabis-derived treatments for various medical conditions. As these new products move through development pipelines and regulatory approvals, the segment is poised for strong growth. The report also stresses that companies holding regulatory approvals enjoy a competitive advantage in market credibility and trust among healthcare professionals. Smaller players seek market share through innovative formulations for specific medical conditions, though winning regulatory approvals remains a challenge where cannabis rules are strict.

Distribution Channels: Online Pharmacies and Hospitals

By distribution channel, online pharmacies hold the largest market share, driven by convenience and rising demand for cannabis-based medications. The rise of digital health platforms and e-commerce has made access easier, particularly in regions with established programs. Online pharmacies benefit from broader product availability, discreet purchasing options, and the ability to reach patients in remote areas. The hospital segment is experiencing the highest growth rate, fueled by the integration of cannabis-based treatments into mainstream medical practice, especially for cancer-related symptoms and neurological disorders, and by the inclusion of cannabis medicines in treatment protocols.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/cannabis-pharmaceuticals-market

Europe and Asia Pacific: Different Stages of Maturity

The Europe market is growing steadily, with the UK, Germany, and the Netherlands leading regional share. Germany is one of the largest markets in Europe thanks to its well-established framework. Research continues into cannabis-based therapies for conditions such as epilepsy and multiple sclerosis, and while regulatory barriers remain in some countries, the overall trend is toward expanding access. Asia Pacific is still in the early stages, with significant variation in regulatory approaches. Australia has made notable progress, with both production and prescriptions increasing, and South Korea is gradually expanding, while China and India maintain stringent regulations. Many companies focus on pharmaceutical-grade products with scientific validation, and the evolving regulatory landscape will keep shaping competition.

Competitive Strategies and Industry Developments

Competition is shaped by the regulatory environment and clinical efficacy. GW Pharmaceuticals, now part of Jazz Pharmaceuticals, markets the CBD-based epilepsy drug and Sativex, while Tilray has a strong presence in Canada and the US. Companies are expanding research capabilities through partnerships with academic institutions and research organizations, and many are pursuing mergers and acquisitions to broaden portfolios. In July 2025, HYTN Innovations Inc. of Canada obtained a Cannabis Drug License from Health Canada, expanding its ability to manufacture cannabis-derived pharmaceutical products and supporting its strategy to become a leading supplier of GMP-grade cannabinoid APIs and finished formulations.

Key Players

•         Altria Group (parent company of Cronos Group)

•         Aphria (now part of Tilray)

•         Aurora Cannabis

•         Cannabis Science

•         Canopy Growth

•         Charlotte's Web

•         Cresco Labs

•         Green Thumb Industries

•         GW Pharmaceuticals (now part of Jazz Pharmaceuticals)

•         Hexo Corporation

•         MedReleaf

•         Organigram

•         Tilray

•         Tilray Health

•         Zynerba Pharmaceuticals

Conclusion

Brand type and distribution channel together show where the cannabis pharmaceuticals market is heading. Established brands retain strength, newer brands are growing fastest, and online pharmacies and hospitals are broadening patient access. With the market forecast at USD 357.96 billion by 2034, companies that secure credibility, manage regulatory complexity, and build supply capability will be best prepared to compete across regions at different stages of maturity.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market